Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Cash from Financing Activities: 2023-2025

Historic Cash from Financing Activities for Mereo BioPharma Group (MREO) over the last 1 years, with Jun 2025 value amounting to -$134,000.

  • Mereo BioPharma Group's Cash from Financing Activities fell 100.29% to -$134,000 in Q2 2025 from the same period last year, while for Jun 2025 it was -$346,000, marking a year-over-year change of. This contributed to the annual value of $46.1 million for FY2024, which is 478.79% up from last year.
  • Mereo BioPharma Group's Cash from Financing Activities amounted to -$134,000 in Q2 2025, which was down 131.75% from $422,000 recorded in Q1 2025.
  • Mereo BioPharma Group's 5-year Cash from Financing Activities high stood at $46.8 million for Q2 2024, and its period low was -$594,000 during Q3 2024.
  • In the last 3 years, Mereo BioPharma Group's Cash from Financing Activities had a median value of $191,000 in 2024 and averaged $9.1 million.
  • Data for Mereo BioPharma Group's Cash from Financing Activities shows a maximum YoY tumbled of 107.51% (in 2024) over the last 5 years.
  • Mereo BioPharma Group's Cash from Financing Activities (Quarterly) stood at $7.9 million in 2023, then slumped by 107.51% to -$40,000 in 2024, then plummeted by 100.29% to -$134,000 in 2025.
  • Its Cash from Financing Activities was -$134,000 in Q2 2025, compared to $422,000 in Q1 2025 and -$40,000 in Q4 2024.